Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D03IKZ
|
||||
Former ID |
DIB000970
|
||||
Drug Name |
HBP-347
|
||||
Synonyms |
HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University
|
||||
Indication | Autoimmune diabetes [ICD10:E08-E13] | Discontinued in Phase 3 | [550048] | ||
Company |
Weizmann Institute of Science
|
||||
Target and Pathway | |||||
Target(s) | Heat shock protein HSP90 | Target Info | Modulator | [550909] | |
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.